Finding diabetes and treating it early can prevent high healthcare costs in the long term, the authors day.
A study published in the Journal of the American Osteopathic Association finds that the test for glycated hemoglobin (A1C) can be used to detect undiagnosed diabetes among patients with hyperglycemia, or high blood sugar.
Researchers reviewed medical records of 348 patients with hyperglycemia, who were admitted to a rural community teaching hospital. Of the group, 50 patients had no known history of diabetes, and 31 were given the A1C test, which measures blood glucose levels over the previous 8 to 12 weeks.
Among those tested, 77% had results consistent with diabetes (58%) or prediabetes (19%). More than half (55%) were discharged with a diagnosis including diabetes, despite no history of this disease in existing records.
“In the hospital, we often find hyperglycemia when we’re treating other illnesses, like sepsis or heart attack,” said Jay Shurbrook, DO, a professor of primary care at Touro University in California. “This study found that patients with no known history of diabetes whose A1C level was measured were more than 5 times more likely to leave the hospital with a diagnosis of new onset diabetes.”
Shurbrook said the study shows there are opportunities to find those with diabetes and treat them, reducing high healthcare expenditures over the long term. In addition, the finding of a sizable number of patients with prediabetes also affords providers a chance to intervene before full-blown diabetes develops.
“From the osteopathic perspective of early detection equals better outcomes, it’s easy to make a case for hospital protocols to trigger an A1C test when hyperglycemia is detected, to distinguish between transient hyperglycemia and chronic disease.”
The American Diabetes Association reported that 20% of healthcare dollars are spent on diabetes, including $1 of every $3 spent by Medicare. The authors said in a statement that earlier studies show that once diabetes is detected, proper inpatient education can lower rates of all-cause 30-day readmission.
Reference
Jones D, Scharfenberg B, Perkins J, Childers K, Dogbey GY, Shurbrook JH. Glycated hemoglobin testing to identify undiagnosed diabetes mellitus in the inpatient setting. J Am Osteopath Assoc. 2016;116:350-357.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More